QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

GENB

QT73Generate Biomedicines, Inc.
NASDAQ·Financial Services·Asset Management·USA
Latest market price
14.49
+0.62+4.47%
OverviewShort InterestFilings
GENBQT73Generate Biomedicines, Inc.·NASDAQ
OverviewShort InterestFilings
14.49+4.47%
TA
Loading chart...
Screen all →
BLK-0.69%$1050.09BX-0.98%$123.79BK-1.03%$142.50BN-0.67%$44.44KKR-0.16%$97.01APO-1.01%$137.50APOS+0.08%$25.60BAM-1.13%$47.44
Snapshot
Index-P/E-EPS (ttm)-
Insider Own-
Shs Outstand128.19M
Perf Week12.06%
Market Cap1.78BForward P/E-EPS next Y-2.14Insider Trans-Shs Float-Perf Month16.67%
Enterprise Value1.72BPEG-EPS next Q-0.51Inst Own-Short Float-Perf Quarter17.90%
Income-519895900.00P/S55.75EPS this Y-Inst Trans-Short Ratio-Perf Half Y-
Sales31.89MP/B-EPS next Y4.03%ROA-61.53%Short Interest-Perf YTD-
Book/sh-4.86P/C-EPS next 5Y-ROE38.68%52W High-Perf Year-
Cash/sh1.72P/FCF-EPS past 3/5Y-ROIC-89.38%52W Low-Perf 3Y-
Dividend Est.-EV/EBITDA-8.27Sales past 3/5Y-Gross Margin100.00%Volatility4.47% 5.18%Perf 5Y-
Dividend TTM-EV/Sales54.08EPS Y/Y TTM-Oper. Margin-737.04%ATR (14)1.09Perf 10Y-
Dividend Ex-Date-Quick Ratio2.85Sales Y/Y TTM-Profit Margin-636.99%RSI (14)56.44Recom2.00
Dividend Gr. 3/5Y-Current Ratio2.85EPS Q/Q-SMA208.82%Beta1.33Target Price23.50
Payout0.00%Debt/Eq-0.11Sales Q/Q-SMA508.54%Rel Volume4.06Prev Close13.87
Employees312LT Debt/Eq-0.09EarningsSep 02SMA200-Avg Volume641.60KPrice14.49
IPO DateFeb 27, 2026Option/ShortNo / YesEPS/Sales Surpr.-Net Debt/EBITDA0.25Volume2,602,642Change4.47%
Analyst Ratings
DateActionAnalystRatingTarget
May-14-26ReiteratedMorgan StanleyOverweight$22
May-08-26ReiteratedH.C. Wainwright$16 → $25
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
Total Revenue3220
Cost of Goods Sold Incl. D&A
00
Gross Profit3220
Selling, General and Administrative Excl. Other4242
Research and Development225175
Other Operating Expense
00
Operating Income-235-197
Interest Expense12
Unusual Expense
——
Non-Operating Income (Expense)-13-18
Net Income Before Taxes-223-181
Income Taxes
00
Consolidated Net Income-203-174
Net Income From Continuing Operations-223-181
Net Income-203-174
EPS (Recurring)-4.98-1.68
EPS (Basic, Before Extraordinaries)-4.98-1.68
EPS (Diluted)-4.98-1.68
EBITDA-208-164
Other After Tax Adjustments
——
Stock Option Compensation Expense
——
Price To Earnings Ratio
——
Price To Sales Ratio
——
Gross Margin100.00100.00
Operating Margin-734.38-985.00
Net Margin-634.38-870.00
Shares Outstanding50127
Market Capitalization
——
Operating Lease Expense
——
Insider Trading Volume
$15.36$13.65$11.94$10.23$8.52● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR